30 CHF CHF 30.00
AG-CR1-3678-M500500 mgCHF 30.00
AG-CR1-3678-G0011 gCHF 55.00
|Synonyms||β-GPA; PNU 10483; N-(Aminoiminomethyl)-β-alanine|
|Solubility||Soluble in water (50mg/ml) or other aqueous buffers (e.g. PBS).|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
Keep cool and dry.
Aqueous solutions should not be stored for longer than one day.
Stable for at least 2 years after receipt when stored at -20°C.
Store solutions at -20°C in the dark.
|Product Specification Sheet|
- Competitive creatine uptake inhibitor.
- Creatine analog that alters skeletal muscle energy expenditure.
- Thermogenesis inhibitor. Inhibitor of energy expenditure through reduction of ATP.
- AMPK stimulator and PGC-1α activator. Reduces cellular ATP, creatine and phosphocreatine levels, consequently stimulating AMP-activated protein kinase (AMPK) and activating PPARγ coactivator 1α (PGC-1α).
- Evokes a shift from glycolytic to oxidative metabolism, increased cellular glucose uptake and increased fatigue tolerance.
- Ameliorates hyperglycemia in animal models of non-insulin-dependent diabetes (NIDDM). Improved insulin sensitivity and promoted weight loss selectively from adipose tissue.
- Studied for potential use during protein refolding as an anti-aggregatory molecule similar to L-arginine.
- Energy metabolism of skeletal muscle containing cyclocreatine phosphate. Delay in onset of rigor mortis and decreased glycogenolysis in response to ischemia or epinephrine: T.M. Annesley & J.B. Walker; J. Biol. Chem. 255, 3924 (1980)
- Biochemical adaptation in the skeletal muscle of rats depleted of creatine with the substrate analogue β-guanidinopropionic acid: E.A. Shoubridge, et al.; Biochem. J. 232, 125 (1985)
- Antihyperglycemic action of guanidinoalkanoic acids: 3-guanidinopropionic acid ameliorates hyperglycemia in diabetic KKAy and C57BL6Job/ob mice and increases glucose disappearance in rhesus monkeys: M.D. Meglasson, et al.; J. Pharmacol. Exp. Ther. 266, 1454 (1993)
- Synthesis and biological activity of analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid: discovery of a novel aminoguanidinoacetic acid antidiabetic agent: S.D. Larsen, et al.; J. Med. Chem. 44, 1217 (2001)
- Aging-associated reductions in AMP-activated protein kinase activity and mitochondrial biogenesis: R.M. Reznick, et al.; Cell Metab. 5, 151 (2007)
- Impaired PGC-1α function in muscle in Huntington's disease: R.K. Chaturvedi, et al.; Hum. Mol. Gen. 18, 3048 (2009)
- The effect of the creatine analogue beta-guanidinopropionic acid on energy metabolism: a systematic review: I. Oudman, et al.; PLoS One 8, e52879 (2013) (Review)
- Genetic depletion of adipocyte creatine metabolism inhibits diet-induced thermogenesis and drives obesity: L. Kazak, et al.; Cell Metab. 26, 660 (2017)
- Creatine fuels the thermic effect of feeding: A.R. Saltiel; Cell Metab. 26, 594 (2017) (Review)
- β-GPA treatment leads to elevated basal metabolic rate and enhanced hypoxic exercise tolerance in mice: T.T. Ross, et al.; Physiol. Rep. 5, e13192 (2017)